Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Company Data

Name Lipella Pharmaceuticals Inc. - Common Stock

Company Lipella Pharmaceuticals Inc.

Symbol LIPO

Website https://www.lipella.com

Primary Exchange

NASDAQ

ISIN US53630L1008

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Jonathan Kaufman

Country United States of America

Currency USD

Employees 0,0 T

Address 7800 Susquehanna St., 15208 Pittsburgh

IPO Date 2022-12-19

Stock Splits

Date	Split
08.11.2024	1:8

Ticker Symbols

Name	Symbol
NASDAQ	LIPO

More Shares

Investors who hold Lipella Pharmaceuticals Inc. - Common Stock also have the following shares in their portfolio:

ASTRONICS CORP Share

TXNM ENERGY 25/54 CV Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog